Poxel
LYON, FR· latest recorded location
POXEL is named on 31 US grants and 38 published applications in this corpus. Its most frequent classification is A61P (Therapeutic uses of medicines).
- Granted patents
- 31
- Published applications
- 38
- Inventors
- 52
- Granted in 2026 so far
- 0
- Most recent grant
- 3 Jun 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 3 |
| 2011 | 0 | 1 |
| 2012 | 2 | 2 |
| 2013 | 2 | 5 |
| 2014 | 4 | 1 |
| 2015 | 3 | 1 |
| 2016 | 3 | 1 |
| 2017 | 0 | 0 |
| 2018 | 2 | 1 |
| 2019 | 1 | 0 |
| 2020 | 1 | 7 |
| 2021 | 3 | 2 |
| 2022 | 2 | 6 |
| 2023 | 3 | 5 |
| 2024 | 3 | 0 |
| 2025 | 2 | 2 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 69 documents
Recent patents
- Monohydrate potassium salt of a thienopyridone derivative and its preparation process3 Jun 2025US 12,319,700 B2
- Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (ADPKD)27 May 2025US 12,310,949 B2
- Methods of treating subjects having diabetes with chronic kidney disease16 Jul 2024US 12,036,226 B2
- Deuterium-enriched pioglitazone5 Mar 2024US 11,918,567 B2
- 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same5 Mar 2024US 11,918,569 B2
- Use of a thienopyridone derivative in the treatment of diabetic nephropathy30 Jul 2026US 2026/0216147 A1
- Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone28 Aug 2025US 2025/0268879 A1
- Monohydrate potassium salt of a thienopyridone derivative and its preparation process15 May 2025US 2025/0154164 A1
- Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disorders13 Jul 2023US 2023/0218595 A1
- Use of a thienopyridone derivative in the treatment of diabetic nephropathy18 May 2023US 2023/0149370 A1
Most cited
By later US patents
- Combination of insulin with triazine derivatives5US 8,592,370 B22013
- Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect4US 8,217,040 B22012
- Combination of triazine derivatives and insulin secretion stimulators4US 8,227,465 B22012
- Method for the production of 3,6-dihydro-L, 3, 5-triazine derivatives from metformin and paraldehyde derivatives4US 8,461,331 B22013
- Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization4US 8,742,102 B22014